MARKET INDEX
KOSPI5,290.53▼ 0.98%
KOSDAQ699.66▲ 0.45%
S&P 5007,561.67▼ 0.40%
NASDAQ25,136.27▼ 0.91%
USD/KRW1,336.38▲ 1.27 (+0.10%)
WTI Crude$88.48▼ 0.09%
BTC/USD$65,301▲ 1.84%
KOSPI5,290.53▼ 0.98%
KOSDAQ699.66▲ 0.45%
S&P 5007,561.67▼ 0.40%
NASDAQ25,136.27▼ 0.91%
USD/KRW1,336.38▲ 1.27 (+0.10%)
WTI Crude$88.48▼ 0.09%
BTC/USD$65,301▲ 1.84%
헤더 좌
헤더 우
BREAKING
MARKET Times 공식 배너

Alteogen Targets Monthly Obesity Injections, Outperforming Eli Lilly’s Retatrutide in Animal Studies

Preclinical results unveiled at ObesityWeek: 55.3% weight loss vs. 49.0% for Retatrutide Fourfold longer half-life and superior weight regain suppression mark first milestone for ultra-long-acting platform The global obe

Alteogen Targets Monthly Obesity Injections, Outperforming Eli Lilly’s Retatrutide in Animal Studies
MTIMES Archive / Photo

Preclinical results unveiled at ObesityWeek: 55.3% weight loss vs. 49.0% for Retatrutide

Fourfold longer half-life and superior weight regain suppression mark first milestone for ultra-long-acting platform

The global obesity treatment market, currently dominated by once-weekly injections, is seeing an intensifying race to develop long-acting, once-monthly formulations. Alteogen (196170) has presented animal study data at a major U.S. obesity conference, demonstrating higher weight loss efficacy and lower weight regain rates compared to Eli Lilly’s next-generation candidate, Retatrutide, signaling the potential for a once-monthly treatment.

Alteogen announced on the 16th that it presented preclinical research results for its ALT-M5 series, which utilizes the company's proprietary ultra-long-acting platform, at 'ObesityWeek 2026' in Washington, D.C.

The study evaluated drug persistence, weight loss efficacy, and post-treatment weight changes by comparing the candidate against industry benchmarks such as Retatrutide and Tirzepatide.

55.3% Weight Reduction Surpasses Retatrutide’s 49.0%

Retatrutide, a triple-agonist candidate currently under development by Eli Lilly, is noted for its potent weight loss effects. Alteogen used this as a primary benchmark to evaluate its own drug's performance.

Alteogen utilized the ALT-M5B4 variant to assess drug persistence and ALT-M5B418 to evaluate weight loss and post-cessation weight maintenance.

In the persistence study, the half-life of ALT-M5B4 was measured at 68.1 hours—more than four times longer than that of Retatrutide—following a single subcutaneous injection in test animals.

In a separate experiment assessing weight loss, ALT-M5B418 outperformed the competition. Diet-induced obese (DIO) mice treated with twice-weekly subcutaneous injections of ALT-M5B418 showed a 55.3% reduction in body weight by day 21. In the same study, Retatrutide showed a 49.0% reduction, while Tirzepatide showed 21.0%.

Differences were also observed in weight maintenance after treatment cessation. Two weeks after stopping the medication, the weight regain rate for ALT-M5B418 was 34.7%, which was 9.5 percentage points lower than Retatrutide’s 44.2%.

While high weight loss efficacy is critical, preventing weight regain after treatment is a major challenge in obesity management. Alteogen stated that this study confirms both the efficacy of weight reduction and the potential for sustained weight maintenance. These findings are based on animal models, and human clinical trials are required to verify if similar effects will manifest in patients.

From Once-Weekly to Once-Monthly: The Race for Convenience

Current market leaders, Wegovy and Mounjaro, are once-weekly injections. The industry is now shifting toward long-acting formulations to reduce dosing frequency and improve treatment adherence.

A once-monthly formulation could reduce the annual number of injections from 52 to 12. If such a treatment can maintain stable efficacy while reducing the burden on patients, it would offer a significant new option for those requiring long-term obesity management.

Alteogen’s ALT-M5 is the company’s first project targeting this market shift. By advancing technology that selectively conjugates drugs to specific protein sites, the company developed an ultra-long-acting platform that binds multiple active molecules to extend efficacy. The company completed a Patent Cooperation Treaty (PCT) filing for this platform in September.

While Alteogen has previously focused on its Hybrozyme technology to convert intravenous drugs into subcutaneous formulations, this new platform focuses on extending the drug's half-life, potentially expanding its application beyond obesity treatments.

Alteogen CEO Park Soon-jae stated, "Our research, which compared our candidate against Retatrutide—the most potent obesity treatment currently announced—showed superior results in weight loss, suppression of weight regain, and drug persistence." He added, "Building on our Hybrozyme success, we will continue to expand the utility of our new ultra-long-acting platform to develop obesity treatments that offer both superior convenience and weight maintenance."

MARKET Times

MTIMES Global Editorial Statement

This analysis is provided for international business intelligence and informational purposes only. It does not constitute investment advice or a solicitation to buy or sell securities. For inquiries regarding licensing or syndication, please contact [email protected].

← More in CorporateBack to Top ↑

Related Market & Corporate Intelligence

European Equities See Largest Inflow in Five Years as Investor Focus Shifts from US TechEuropean Equities See Largest Inflow in Five Years as Investor Focus Shifts from US TechCan KOSDAQ Revitalization Succeed? Focus Shifts to Delisting Insolvent FirmsCan KOSDAQ Revitalization Succeed? Focus Shifts to Delisting Insolvent FirmsK-Bio at a Crossroads: AriBio and HLB Therapeutics Await Pivotal Phase 3 ResultsK-Bio at a Crossroads: AriBio and HLB Therapeutics Await Pivotal Phase 3 ResultsAnthropic IPO Draws Sixfold Oversubscription as Expected Buying Surge NearsAnthropic IPO Draws Sixfold Oversubscription as Expected Buying Surge Nears
HomeTOP10AlmatenPicksCorpAlgiten